Patents Assigned to Gilead Sciences, Inc.
  • Antibodies to matrix metalloproteinase 9
    Patent number: 11634505
    Abstract: The present disclosure provides compositions and methods of use involving binding proteins, e.g., antibodies and antigen-binding fragments thereof, that bind to the matrix metalloproteinase-9 (MMP9) protein (MMP9 is also known as gelatinase-B), such as where the binding proteins comprise an immunoglobulin (Ig) heavy chain (or functional fragment thereof) and an Ig light chain (or functional fragment thereof).
    Type: Grant
    Filed: September 10, 2020
    Date of Patent: April 25, 2023
    Assignee: Gilead Sciences, Inc.
    Inventors: Victoria Smith, Scott McCauley
  • GLP-1R MODULATING COMPOUNDS
    Publication number: 20230102927
    Abstract: The present disclosure provides GLP-1R agonists, and compositions, methods, and kits thereof. Such compounds are generally useful for treating a GLP-1R mediated disease or condition in a human.
    Type: Application
    Filed: April 19, 2022
    Publication date: March 30, 2023
    Applicants: Gilead Sciences, Inc., Gilead Sciences, Inc.
    Inventors: Megan K. Armstrong, James S. Cassidy, Elbert Chin, Chienhung Chou, Jeromy J. Cottell, Chao-I Hung, Kavoos Kolahdouzan, David W. Lin, Michael L. Mitchell, Ezra Roberts, Scott D. Schroeder, Nathan D. Shapiro, James G. Taylor, Rhiannon Thomas-Tran, Nathan E. Wright, Zheng-Yu Yang
  • Substituted pyridotriazine compounds and uses thereof
    Patent number: 11613546
    Abstract: The present disclosure relates generally to certain tricyclic compounds, pharmaceutical compositions comprising said compounds, and methods of making said compounds and pharmaceutical compositions. The compounds of the disclosure are useful in treating or preventing human immunodeficiency virus (HIV) infection.
    Type: Grant
    Filed: January 18, 2022
    Date of Patent: March 28, 2023
    Assignee: Gilead Sciences, Inc.
    Inventors: Hang Chu, Ana Z. Gonzalez Buenrostro, Hongyan Guo, Xiaochun Han, Anna E. Hurtley, Lan Jiang, Jiayao Li, David W. Lin, Michael L. Mitchell, Devan Naduthambi, Gregg M. Schwarzwälder, Suzanne M. Szewczyk, Matthew J. Von Bargen, Qiaoyin Wu, Hong Yang, Jennifer R. Zhang
  • Methods of preparing 1?-cyano nucleosides
    Patent number: 11613553
    Abstract: The present disclosure generally describes methods of preparing 1?-cyano nucleosides, such as a compound of Formula (I). For example, the compound of Formula (I) can be prepared from a compound of Formula (II-a) in a flow reactor.
    Type: Grant
    Filed: March 11, 2021
    Date of Patent: March 28, 2023
    Assignee: Gilead Sciences, Inc.
    Inventors: Pavel R. Badalov, Stacy Bremner, Matthew R. Chin, Detian Gao, Nolan Griggs, Lars V. Heumann, Chiajen Lai, Robert R. Milburn, Sankar Mohan, Sean T. Neville, Bing Shi, Andrew C. Stevens, Nicholas A. J. Uhlig, Tiago Vieira, Todd A. Wenderski
  • Crystalline forms of (S)-2-ethylbutyl 2-(((S)-(((2R,3S,4R,5R)-5-(4-aminopyrrolo[2,1-f] [1,2,4]triazin-7-yl)-5-cyano-3,4-dihydroxytetrahydrofuran-2-yl)methoxy) (phenoxy) phosphoryl)amino)propanoate
    Patent number: 11597742
    Abstract: The present invention relates to novel salts and crystalline forms of (S)-2-ethylbutyl 2-(((S)-(((2R,3S,4R,5R)-5-(4-aminopyrrolo[2,1-f][1,2,4]triazin-7-yl)-5-cyano-3,4-dihydroxytetrahydrofuran-2-yl)methoxy)(phenoxy)phosphoryl)amino)propanoate for use in treating viral infections. In some embodiments, the viral infection is caused by a virus selected from the group consisting of Arenaviridae, Coronaviridae, Filoviridae, Flaviviridae, and Paramyxoviridae.
    Type: Grant
    Filed: October 13, 2020
    Date of Patent: March 7, 2023
    Assignee: Gilead Sciences, Inc.
    Inventors: Katrien Brak, Ernest A. Carra, Lars V. Heumann, Nate Larson
  • Multispecific antibodies that target HIV GP120 and CD3
    Patent number: 11597759
    Abstract: Multispecific antibodies (e.g., bispecific antibodies) that bind to HIV gp120 and CD3 are disclosed. Also disclosed are methods of using such antibodies to treat or prevent HIV infection.
    Type: Grant
    Filed: May 6, 2020
    Date of Patent: March 7, 2023
    Assignee: GILEAD SCIENCES, INC.
    Inventors: Tomas Cihlar, Joshua Goldsmith, George Kukolj, Craig S. Pace, Doug Rehder, Matthew R. Schenauer, Derek Dean Sloan, Heather Theresa Stephenson, Nathan D. Thomsen
  • Methods of treating a retroviral infection
    Patent number: 11583581
    Abstract: The invention relates to a non-coding sequence of deoxyribonucleic acids comprising at least one sequence motif N1N2CGN3N4, wherein N is a nucleotide comprising A, C, T, or G, and C is deoxycytidine, G is deoxyguanosine, A is deoxyadenosine and T is deoxy-thymidine for the treatment of viral infections. In particular, the non-coding sequence of deoxyribonucleic acids is used in combination with antiretroviral therapy and/or histone de-acetylase inhibitors.
    Type: Grant
    Filed: September 21, 2016
    Date of Patent: February 21, 2023
    Assignee: Gilead Sciences, Inc.
    Inventors: Matthias Schroff, Manuel Schmidt, Kerstin Kapp, Alfredo Zurlo, Ole Schmeltz Sogaard, Martin Tolstrup, Rasmus Offersen
  • LPA receptor antagonists and uses thereof
    Patent number: 11584738
    Abstract: The present disclosure relates generally to compounds that bind to Lysophosphatidic Acid Receptor 1 (LPAR1) and act as antagonists of LPAR1. The disclosure further relates to the use of the compounds for the preparation of a medicament for the treatment of diseases and/or conditions through binding of LPAR1, including fibrosis and liver diseases such as non-alcoholic steatohepatitis (NASH), interstitial lung disease (ILD), or chronic kidney disease (CKD).
    Type: Grant
    Filed: May 13, 2021
    Date of Patent: February 21, 2023
    Assignee: Gilead Sciences, Inc.
    Inventors: Brian P. Bestvater, Zhimin Du, Julie Farand, Joshua A. Kaplan, Barton W. Phillips, Doris T. Tang, Chandrasekar Venkataramani, Peiyuan Wang, Kin S. Yang, Anna Zagorska
  • Solid forms of a toll-like receptor modulator
    Patent number: 11583531
    Abstract: The present disclosure provides crystalline forms, solvates and hydrates of (R)-2-((2-amino-7-fluoropyrido[3,2-d]pyrimidin-4-yl)amino)-2-methylhexan-1-ol, and methods of making.
    Type: Grant
    Filed: April 15, 2020
    Date of Patent: February 21, 2023
    Assignee: Gilead Sciences, Inc.
    Inventors: Sylvie M. Asselin, Pavel R. Badalov, Henry G. Morrison, Christopher S. Regens, Tiago Vieira
  • Combination comprising immunostimulatory oligonucleotides
    Patent number: 11578331
    Abstract: The invention relates to a combination and its use for the treatment of diseases. The instant disclosure provides a combination of a so-called T-cell regulator selected from the group comprising PD1, PD-L1, OX40, TIM-3, LAG3, CD137(4-1BB) and a non-coding immunomodulating DNA.
    Type: Grant
    Filed: February 18, 2020
    Date of Patent: February 14, 2023
    Assignee: Gilead Sciences, Inc.
    Inventors: Matthias Schroff, Manuel Schmidt, Kerstin Kapp, Alfredo Zurlo
  • Compounds for inhibition of ?4 ?7 integrin
    Patent number: 11578069
    Abstract: The present disclosure provides a compound of Formula (I): or a pharmaceutically acceptable salt thereof as described herein. The present disclosure also provides pharmaceutical compositions comprising a compound of Formula (I), processes for preparing compounds of Formula (I), therapeutic methods for treating inflammatory disease.
    Type: Grant
    Filed: August 12, 2020
    Date of Patent: February 14, 2023
    Assignee: GILEAD SCIENCES, INC.
    Inventors: Peter A. Blomgren, Taryn L. Campbell, Jayaraman Chandrasekhar, Christopher T. Clark, Kevin S. Currie, Jeffrey E. Kropf, Yasamin Moazami, Nicole A. Nava, Leena Patel, Jason K. Perry, Natalie Seeger, Kirk L. Stevens, Zhongdong Zhao
  • Antibodies and fragments thereof that bind hepatitis B virus protein X
    Patent number: 11578117
    Abstract: Provided herein are, inter alia, antibodies, antigen-binding antibody fragments, cells, polynucleotides, compositions, kits, and methods relating to the detection of HBV protein X (HBx), e.g., in vitro and in vivo. Included are antibodies and fragments thereof that bind HBx, as well as kits, cells, and compositions comprising such antibodies and fragments.
    Type: Grant
    Filed: November 12, 2020
    Date of Patent: February 14, 2023
    Assignee: Gilead Sciences, Inc.
    Inventors: Simon Paul Fletcher, Christian Alfons Voitenleitner
  • CAPSID INHIBITORS FOR THE TREATMENT OF HIV
    Publication number: 20230038823
    Abstract: The present disclosure relates generally to certain compounds, pharmaceutical compositions comprising said compounds, and methods of making and using said compounds and pharmaceutical compositions. The compounds and compositions disclosed herein may be used for the treatment or prevention of a Retroviridae viral infection, including an infection caused by the HIV virus.
    Type: Application
    Filed: June 24, 2021
    Publication date: February 9, 2023
    Applicant: Gilead Sciences, Inc.
    Inventors: Chienhung Chou, Darryl Kato, Scott E. Lazerwith, Scott D. Schroeder, Winston C. Tse, Jennifer R. Zhang
  • Pyrrolo[1,2-b]pyridazine derivatives
    Patent number: 11572362
    Abstract: A compound of Formula (I): pharmaceutically acceptable salts thereof, deuterated analogs thereof, compositions thereof, and methods of treating disease using a compound thereof are disclosed.
    Type: Grant
    Filed: August 13, 2019
    Date of Patent: February 7, 2023
    Assignee: Gilead Sciences, Inc.
    Inventors: Stephen Ammann, Elizabeth M. Bacon, Gediminas Brizgys, Elbert Chin, Chienhung Chou, Jeromy J. Cottell, Marilyn Ndukwe, James G. Taylor, Nathan E. Wright, Zheng-Yu Yang, Sheila M. Zipfel
  • PD-1/PD-L1 inhibitors
    Patent number: 11555029
    Abstract: Compounds of Formula (I), methods of using said compounds singly or in combination with additional agents and compositions of said compounds for the treatment of cancer are disclosed.
    Type: Grant
    Filed: June 3, 2020
    Date of Patent: January 17, 2023
    Assignee: Gilead Sciences, Inc.
    Inventors: Evangelos Aktoudianakis, Aesop Cho, Zhimin Du, Michael Graupe, Lateshkumar Thakorlal Lad, Paulo A. Machicao Tello, Jonathan William Medley, Samuel E. Metobo, Prasenjit Kumar Mukherjee, Devan Naduthambi, Eric Q. Parkhill, Barton W. Phillips, Scott Preston Simonovich, Neil H. Squires, Peiyuan Wang, William J. Watkins, Jie Xu, Kin Shing Yang, Christopher Allen Ziebenhaus
  • Bridged tricyclic carbamoylpyridone compounds and their pharmaceutical use
    Patent number: 11548902
    Abstract: Compounds for use in treating or preventing human immunodeficiency virus (HIV) infection are disclosed. The compounds have the following formula (I): including stereoisomers and pharmaceutically acceptable salts thereof, wherein R1, R2, L, W1, W2, X, Y, and Z are as defined herein. Methods associated with the preparation and use of such compounds, as well as pharmaceutical compositions comprising such compounds, are also disclosed.
    Type: Grant
    Filed: June 29, 2021
    Date of Patent: January 10, 2023
    Assignee: Gilead Sciences, Inc.
    Inventors: Hang Chu, Ana Z. Gonzalez Buenrostro, Hongyan Guo, Xiaochun Han, Lan Jiang, Jiayao Li, Michael L. Mitchell, Hyung-Jung Pyun, Scott D. Schroeder, Gregg M. Schwarzwälder, Nathan D. Shapiro, Devleena M. Shivakumar, Qiaoyin Wu, Hong Yang, Jennifer R. Zhang
  • Triazole carbamate pyridyl sulfonamides as LPA receptor antagonists and uses thereof
    Patent number: 11548871
    Abstract: The present disclosure relates generally to compounds that bind to Lysophosphatidic Acid Receptor 1 (LPAR1) and act as antagonists of LPAR1. The disclosure further relates to the use of the compounds for the preparation of a medicament for the treatment of diseases and/or conditions through binding of LPAR1, including fibrosis and liver diseases such as non-alcoholic steatohepatitis (NASH).
    Type: Grant
    Filed: November 12, 2020
    Date of Patent: January 10, 2023
    Assignee: Gilead Sciences, Inc.
    Inventors: Brian P. Bestvater, Zhimin Du, Julie Farand, Gregory Notte, Barton W. Phillips, Doris T. Tang, Chandrasekar Venkataramani, Peiyuan Wang, Kin S. Yang, Anna Zagorska
  • Substituted 1,4-methanopyrido[1?,2?:4,5]pyrazino[1,2-a]pyrimidines for treating viral infections
    Patent number: 11548901
    Abstract: Compounds for use in the treatment of human immunodeficiency virus (HIV) infection are disclosed. The compounds have the following Formula (I): including stereoisomers and pharmaceutically acceptable salts thereof, wherein R1, X, W, Y1, Y2, Z1, and Z4 are as defined herein. Methods associated with preparation and use of such compounds, as well as pharmaceutical compositions comprising such compounds, are also disclosed.
    Type: Grant
    Filed: May 6, 2020
    Date of Patent: January 10, 2023
    Assignee: Gilead Sciences, Inc.
    Inventors: Elizabeth M. Bacon, Zhenhong R. Cai, Xiaowu Chen, Jeromy J. Cottell, Manoj C. Desai, Mingzhe Ji, Haolun Jin, Scott E. Lazerwith, Michael R. Mish, Philip Anthony Morganelli, Hyung-Jung Pyun, James G. Taylor, Teresa Alejandra Trejo Martin
  • Blister pack
    Patent number: D973512
    Type: Grant
    Filed: July 6, 2022
    Date of Patent: December 27, 2022
    Assignee: GILEAD SCIENCES, INC.
    Inventors: Robert Bridges, Joseph Cordova, Trevor Zimmermann, Caricia Catalani, Kangil Cheon, Hortense Caroline Agnes Desodt, Jesse Arnold Fourt, Brittany Jeannette Margot
  • Blister pack packaging blank
    Patent number: D979401
    Type: Grant
    Filed: December 14, 2020
    Date of Patent: February 28, 2023
    Assignee: GILEAD SCIENCES, INC.
    Inventors: Trevor Zimmermann, Robert Bridges, Joseph Cordova, Gaurav Dabholkar, Alexandra Fideler, Monica Vazirani, Caricia Catalani, Kangil Cheon, Hortense Caroline Agnes Desodt, Jesse Arnold Fourt, Brittany Jeannette Margot